Journals / Türkiye Aile Hekimliği Dergisi / 2015 / Cilt: 19 - Sayı: 4

Is there a relation between statin use and glycemic control in type 2 diabetic patients?

Tip 2 diyabetik hastalarda statin kullanımı ile glisemik kontrol arasında ilişki var mıdır?

Pages
179–186
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Besides increasing diabetes onset, statins also have a significantly negative effect on glucose control during follow up of diabetic patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Statins are used for decades to treat dyslipidemia, and improve cardiovascular mortality.
📊
Key Findings & Data:Although statins are associated with an increase of 9% in diabetes onset; it is not clear how they affect glucose regulation.
💡
Conclusion & Impact:Conclusion: Besides increasing diabetes onset, statins also have a significantly negative effect on glucose control during follow up of diabetic patients
🔬Design:Research Article
📍Scope:2008-2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Statins are used for decades to treat dyslipidemia, and improve cardiovascular mortality. Although statins are associated with an increase of 9% in diabetes onset; it is not clear how they affect glucose regulation. Therefore we aimed to investigate the effect of statins on glycemic control in a sample of Type 2 Diabetes patients. Methods: Patient records of the endocrinology outpatient clinics of a university hospital in Turkey between 2008-2013 were retrospectively investigated according to the inclusion criteria to identify the study sample. The statin treated group enrolled 119 patients, while the non-statin group consisted of 28 patients. Results: Mean age of the study population was 66.8 ± 11.6 (3193) years with a male-to-female ratio of 0.67:1. Mean diabetes duration was 10.5 ± 8.9 years. Statistical comparisons were made by adjusting groups according to age, diabetes duration, anti-diabetic and anti-hypertensive medication. Mean HbA1c percentages in the statin and non-statin group were 7.0 ± 0.1 SEM and 6.4 ± 0.2 SEM respectively (p=0.02). Mean follow-up duration of the study population was 44.3 ± 35.4 (6139) months. Conclusion: Besides increasing diabetes onset, statins also have a significantly negative effect on glucose control during follow up of diabetic patients

Özet

Amaç: Statinler onlarca yıldır dislipidemi tedavisinde kullanılan ajanlar olup kardiyovasküler mortalite üzerinde olumlu etkilere sahiptir. Her ne kadar statinler diyabet başlangıcında %9'luk bir artışla ilişkilendiriliyor olsalar da, glikoz regülasyonunu nasıl etkiledikleri konusu açık değildir. Bu çalışmanın amacı, Tip2 Diyabeti olan bir hasta popülasyonunda statinlerin glisemik kontrolü nasıl etkilediklerini incelemektir. Yöntem: Bu amaçla bir üniversite hastanesinin endokrinoloji polikliniğine 2008-2013 yılları arasında başvuran hastaların kayıtları retrospektif olarak taranmış ve dahil etme kriterleri ışığında bir örneklem belirlenmiştir. Statin kullanan grup 119 hastadan oluşurken, statin kullanmayan grup 28 hastadan oluşmuştur. Bulgular: Örneklemin ortalama yaşı 66,8 ± 11,6 yıl ve erkek-kadın oranı 0,67:1 olarak bulundu. Ortalama diyabet süresi 10,5±8,9 yıldı. Statin kullanan ve kullanmayan gruplar arası karşılaştırmalar yapılırken her iki grup yaş, DM süresi, DM için kullanılan ilaç, anti hipertansif tedavi değişkenleri yönünden istatistiksel olarak eşitlendi. Statin kullanan ve kullanmayan gruplardaki ortalama HbA1c değerleri sırasıyla 7,0±0,1 SEM ve 6,4 ±0,2 SEM olarak bulundu (p=0,02). Çalışma grubunun ortalama izlem süresi 44,3±35,4 aydı. Sonuç: Sonuç olarak statinlerin diyabet başlangıcını arttırmalarının yanısıra diyabetik hastaların izlemi sırasında glikoz regülasyonu üzerinde de anlamlı bir olumsuz etkileri olduğu görülmüştür

🔖

Cite This Article

GEÇKİL, A. Ü., KUT, A., BOŞKUŞ, Y., ÇAYCI, Ö. (2022). Is there a relation between statin use and glycemic control in type 2 diabetic patients?. Türkiye Aile Hekimliği Dergisi, Cilt: 19 - Sayı: 4, 179–186. https://ajindex.com/articles/626743

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes:a systematic review and meta-analysis. Diabetologia 2014; 57(12): 2444-52
  2. Ray K. Statin diabetogenicity: Guidance for clinicians. Cardiovascular Diabetology 2013; 12 (Suppl 1): 3
  3. U.K. Prospective Diabetes Study Group. Ethnicity and cardiovascular disease: The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32). Diabetes Care 1998; 21: 1271–7
  4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl 1): 14-80
  5. Brunzell JD, Davidson M, Furberg CD, et al. American Diabetes Association, American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811–22
  6. Rosenson RS. Statins: Can the new generation make an impression? Expert Opin Emerg Drugs 2004; 9: 269–79
  7. Ma Y, Culver A, Rossouw J, et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? The Adv Cardiovasc Dis 2013; 7(1): 41-4
  8. Rocco MB. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012; 79 (12): 883-93
  9. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103: 357-62
  10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207
  11. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA 2011; 305: 2556-64
  12. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42
  13. Sattar N, Taskinen MR. Statins are diabetogenic – myth or reality? AtherosclerSuppl 2012; 13:1-10
  14. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am CollCardiol 2011; 57:1535-45
  15. Sabatine MS, Wiviott SD, Morrow DA, et al. High-dose atorvastatin associated with